Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2
by
Feng, Carl G.
, Old, Samuel I.
, Baker, Paul J.
, Johnson, Reed F.
, Mayer-Barber, Katrin D.
, Garza, Nicole L.
, Hilligan, Kerry L.
, Laux, Julie
, Clancy, Chad S.
, Peluf, Victoria
, Cohen, Melanie
, O’Mard, Danielle
, Jankovic, Dragana
, Namasivayam, Sivaranjani
, Amaral, Eduardo P.
, Oland, Sandra D.
, Lamiable, Olivier
, Lafont, Bernard A. P.
, Sher, Alan
in
13/1
/ 13/106
/ 13/21
/ 13/31
/ 14/63
/ 38/32
/ 38/91
/ 631/250/127/1212
/ 631/326/596/2553
/ 631/326/596/4130
/ 64/60
/ Animal models
/ Animals
/ Antiviral agents
/ Antiviral drugs
/ Bacteria
/ Bacterial diseases
/ Bacterial infections
/ Bronchopulmonary infection
/ COVID-19
/ COVID-19 - prevention & control
/ Epithelial cells
/ Epithelium
/ Hematopoietic stem cells
/ Humanities and Social Sciences
/ Immunity
/ Infections
/ Interferon
/ Interferon Type I - pharmacology
/ Interferon-gamma
/ Lung
/ Lungs
/ Mice
/ multidisciplinary
/ Pathogenesis
/ SARS-CoV-2
/ Science
/ Science (multidisciplinary)
/ Severe acute respiratory syndrome coronavirus 2
/ Viral diseases
/ γ-Interferon
2023
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2
by
Feng, Carl G.
, Old, Samuel I.
, Baker, Paul J.
, Johnson, Reed F.
, Mayer-Barber, Katrin D.
, Garza, Nicole L.
, Hilligan, Kerry L.
, Laux, Julie
, Clancy, Chad S.
, Peluf, Victoria
, Cohen, Melanie
, O’Mard, Danielle
, Jankovic, Dragana
, Namasivayam, Sivaranjani
, Amaral, Eduardo P.
, Oland, Sandra D.
, Lamiable, Olivier
, Lafont, Bernard A. P.
, Sher, Alan
in
13/1
/ 13/106
/ 13/21
/ 13/31
/ 14/63
/ 38/32
/ 38/91
/ 631/250/127/1212
/ 631/326/596/2553
/ 631/326/596/4130
/ 64/60
/ Animal models
/ Animals
/ Antiviral agents
/ Antiviral drugs
/ Bacteria
/ Bacterial diseases
/ Bacterial infections
/ Bronchopulmonary infection
/ COVID-19
/ COVID-19 - prevention & control
/ Epithelial cells
/ Epithelium
/ Hematopoietic stem cells
/ Humanities and Social Sciences
/ Immunity
/ Infections
/ Interferon
/ Interferon Type I - pharmacology
/ Interferon-gamma
/ Lung
/ Lungs
/ Mice
/ multidisciplinary
/ Pathogenesis
/ SARS-CoV-2
/ Science
/ Science (multidisciplinary)
/ Severe acute respiratory syndrome coronavirus 2
/ Viral diseases
/ γ-Interferon
2023
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2
by
Feng, Carl G.
, Old, Samuel I.
, Baker, Paul J.
, Johnson, Reed F.
, Mayer-Barber, Katrin D.
, Garza, Nicole L.
, Hilligan, Kerry L.
, Laux, Julie
, Clancy, Chad S.
, Peluf, Victoria
, Cohen, Melanie
, O’Mard, Danielle
, Jankovic, Dragana
, Namasivayam, Sivaranjani
, Amaral, Eduardo P.
, Oland, Sandra D.
, Lamiable, Olivier
, Lafont, Bernard A. P.
, Sher, Alan
in
13/1
/ 13/106
/ 13/21
/ 13/31
/ 14/63
/ 38/32
/ 38/91
/ 631/250/127/1212
/ 631/326/596/2553
/ 631/326/596/4130
/ 64/60
/ Animal models
/ Animals
/ Antiviral agents
/ Antiviral drugs
/ Bacteria
/ Bacterial diseases
/ Bacterial infections
/ Bronchopulmonary infection
/ COVID-19
/ COVID-19 - prevention & control
/ Epithelial cells
/ Epithelium
/ Hematopoietic stem cells
/ Humanities and Social Sciences
/ Immunity
/ Infections
/ Interferon
/ Interferon Type I - pharmacology
/ Interferon-gamma
/ Lung
/ Lungs
/ Mice
/ multidisciplinary
/ Pathogenesis
/ SARS-CoV-2
/ Science
/ Science (multidisciplinary)
/ Severe acute respiratory syndrome coronavirus 2
/ Viral diseases
/ γ-Interferon
2023
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2
Journal Article
Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2
2023
Request Book From Autostore
and Choose the Collection Method
Overview
Type-1 and type-3 interferons (IFNs) are important for control of viral replication; however, less is known about the role of Type-2 IFN (IFNγ) in anti-viral immunity. We previously observed that lung infection with
Mycobacterium bovis
BCG achieved though intravenous (
iv
) administration provides strong protection against SARS-CoV-2 in mice yet drives low levels of type-1 IFNs but robust IFNγ. Here we examine the role of ongoing IFNγ responses to pre-established bacterial infection on SARS-CoV-2 disease outcomes in two murine models. We report that IFNγ is required for
iv
BCG induced reduction in pulmonary viral loads, an outcome dependent on IFNγ receptor expression by non-hematopoietic cells. Importantly, we show that BCG infection prompts pulmonary epithelial cells to upregulate IFN-stimulated genes with reported anti-viral activity in an IFNγ-dependent manner, suggesting a possible mechanism for the observed protection. Finally, we confirm the anti-viral properties of IFNγ by demonstrating that the recombinant cytokine itself provides strong protection against SARS-CoV-2 challenge when administered intranasally. Together, our data show that a pre-established IFNγ response within the lung is protective against SARS-CoV-2 infection, suggesting that concurrent or recent infections that drive IFNγ may limit the pathogenesis of SARS-CoV-2 and supporting possible prophylactic uses of IFNγ in COVID-19 management.
The role of interferon-γ (IFNγ) in anti-viral immunity has been unclear. Here the authors show that bacterial-induced or intranasally administered IFNγ effectively restricts SARS-CoV-2 infection in mice through effects on non-hematopoietic cells.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
This website uses cookies to ensure you get the best experience on our website.